Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither evidence from prospective data nor a guideline recommendation, which drug should be preferred over the other. This study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Marijic, Pavo, Schwarzkopf, Larissa, Schwettmann, Lars, Ruhnke, Thomas, Trudzinski, Franziska, Kreuter, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527681/
https://www.ncbi.nlm.nih.gov/pubmed/34666765
http://dx.doi.org/10.1186/s12931-021-01857-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527681/
https://www.ncbi.nlm.nih.gov/pubmed/34666765
http://dx.doi.org/10.1186/s12931-021-01857-y

Ejemplares similares